Ironwood Pharmaceuticals | IRWD - Sales Revenues


Ironwood Pharmaceuticals reported $113.04M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Almirall EUR 602.71M 55.09M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
Ardelyx USD 94.47M 30.74M Mar/2026
Astellas Pharma JPY 640.91B 102.98B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Charles River Laboratories USD 1000M 4.2M Jun/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Halozyme Therapeutics USD 481M 104M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Moderna USD 100M 289M Jun/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Takeda JPY 1.22T 130B Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024